Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
PBM stock price ended at $3.49 on 星期四, after rising 6.40%
On the latest trading day Jun 11, 2026, the stock price of PBM rose by 6.40%, climbing from $3.33 to $3.49. During the session, the stock saw a volatility of 12.90%, with prices oscillating between a daily low of $3.10 and a high of $3.50. Notably, trading volume dropped by 104.6K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 131.7K shares were traded, equating to a market value of approximately $8.0M.